Risk of fluctuations in investment securities values and valuation losses
First written in FY2017. 7 of 17 entries say "Restated". Latest entry: FY2026.
Kidswell Bio moved to the "Worse" side of this theme in 2023, the same year as the typical company in this theme.
The whole theme swung hardest in 2026: 35 of 80 companies on the "Worse" side.
32 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「Impairment loss on investment securities ¥15.797 million」
An impairment loss of ¥15.797 million was recognized on investment securities, and the risk of fluctuations in value and impairment losses was reflected in actual results for the fiscal year. - 2026-05-14MaterialisedRevision of earnings forecasts
「Of the investment securities held by the company, an impairment loss of ¥15.797 million was recognized in the fourth quarter of the consolidated fiscal year ending March 2026 for securities whose fair value was judged to have fallen substantially below their book value.」
An impairment loss of ¥15.797 million was recognized because the fair value of investment securities had fallen substantially. The period's results reflect exposure to fluctuations in the value of investment securities and the related impairment risk. - FY2025Gain on sale and impairment loss recognized in the same periodAnnual report
「Gain on sale of investment securities ¥66.330 million」
A gain of ¥66.330 million was recognized from the partial sale of investment securities, while a separate impairment loss of ¥31.128 million was also recognized. - FY2025-H1MaterialisedAnnual report
「Impairment loss on investment securities ¥14.999 million」
An impairment loss of ¥14.999 million on investment securities was recognized during the current interim consolidated accounting period, bringing the risk of fluctuations in the value of investment securities into actual results. - FY2024-Q2MaterialisedAnnual report
「Impairment loss on investment securities ¥35.000 million」
An impairment loss of ¥35.000 million was recognized on investment securities, and the risk of fluctuations in value and impairment losses was reflected in actual results for the cumulative period of the current quarter. - FY2023MaterialisedAnnual report
「Impairment loss on investment securities ¥31.454 million」
An impairment loss of ¥31.454 million was recognized on investment securities, bringing the risk of fluctuations in value and impairment losses back into actual results. - FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of fluctuations in the value of investment securities and impairment losses. - FY2022MitigatedAnnual report
「The amount of investment securities sold during the consolidated fiscal year was ¥533.765 million, while total gains on sales amounted to ¥417.736 million.」
The company sold the listed securities it had held, reducing its exposure to the risk of fluctuations in the value of investment securities and impairment losses. - FY2022-Q3MitigatedAnnual report
「Gain on sale of investment securities ¥417.736 million」
The sale of the listed securities held by the company was completed, and a gain of ¥417.736 million was recognized. This reduced exposure to the risk of fluctuations in the value of investment securities. - FY2022-Q2Sale of investment securities completedAnnual report
「The gain on the sale of the above investment securities is scheduled to be recognized as an extraordinary gain in the third quarter of the fiscal year ending March 2022.」
The company disclosed that it planned to sell 1 listed security it held and recognize a gain of ¥417.736 million on the sale of investment securities. - FY2020RestatedAnnual report
「As of the date of filing this document, we hold investment securities. Accordingly, if an impairment loss is recognized as a result of fluctuations in the value of these investment securities, it may affect our operating results and financial condition.」
The company continues to disclose the risk of fluctuations in the value of investment securities and impairment losses. - FY2019RestatedAnnual report
「As of the date of filing this document, we hold investment securities. Accordingly, if an impairment loss is recognized as a result of fluctuations in the value of these investment securities, it may affect our operating results and financial condition.」
The company continues to disclose the risk of fluctuations in the value of investment securities and impairment losses. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of fluctuations in the value of investment securities and impairment losses. - FY2018RestatedAnnual report
「As of the date of filing this document, we hold investment securities. Accordingly, if an impairment loss is recognized as a result of fluctuations in the value of these investment securities, it may affect our operating results and financial condition.」
The company continues to disclose the risk of fluctuations in the value of investment securities and impairment losses. No impairment loss was recognized during the fiscal year. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of fluctuations in the value of investment securities and impairment losses. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding the risk of fluctuations in the value of investment securities and impairment losses. - FY2017MaterialisedAnnual report
「Under extraordinary gains and losses, the company has recognized an impairment loss on investment securities.」
The risk of fluctuations in the value of investment securities was disclosed for the first time, and an impairment loss of ¥45.371 million on investment securities was actually recognized during the fiscal year.